Survey 28 - Effectiveness and safety of cefpodoxime in upper respiratory tract infectionsMCI Registration NumberFULL NAME (As in your Pancard)EmailPhone/MobileCityStateSpecialityBank DetailsAccount Holder NameA/c NumberIFSC CodeUpload Cancelled Cheque (Max Size - 2 MB)Choose File Pancard NumberUpload Pancard Details (Max Size - 2 MB)Choose File 1. Compared to Cefixime, Cefpodoxime demonstrates superior activity against which of the following pathogens? Escherichia coli Pneumococci and Staphylococci Pseudomonas aeruginosa Haemophilus influenzae2. What is the tissue penetration advantage of Cefpodoxime over Cefixime? 1.5 times higher 2 times higher 3 times higher Equal penetration3. In acute exacerbations of chronic bronchitis (AECB), what is the clinical efficacy rate of Cefpodoxime? 94.7% 95.2% 97.2% 98.5%4. Compared to Amoxicillin plus Clavulanic acid in AECB, what percentage of patients achieved bacteriological cure with Cefpodoxime? 72.7% 75.0% 80.0% 85.0%5. Which statement best describes Cefixime's activity against Staphylococci? Superior activity Moderate activity Insufficient activity Equal to Cefpodoxime6. For which upper respiratory tract infections has Cefpodoxime shown high cure rates? Acute pharyngitis only Acute maxillary sinusitis and acute tonsillopharyngitis Chronic sinusitis only Allergic rhinitis7. In pediatric patients, Cefpodoxime proxetil is particularly effective for treating: Urinary tract infections Skin and soft tissue infections Acute otitis media (AOM) Gastroenteritis8. What is the primary advantage of Cefpodoxime over Amoxicillin plus Clavulanic acid in AECB treatment? Lower cost Better tolerability only Higher clinical efficacy and bacteriological cure rates Shorter treatment duration9. The safety profile of Cefpodoxime in upper respiratory tract infections is described as: Concerning with multiple side effects Favourable with good tolerability Unknown Similar to penicillin allergies10. For empirical treatment of bacterial acute otitis media in children, Cefpodoxime proxetil is considered: A second-line option Contraindicated An excellent choice Equivalent to other antibiotics11. In comparison studies, Cefpodoxime demonstrated superior potency against pneumococci when compared to: Amoxicillin Cefixime Azithromycin Ciprofloxacin12. What makes Cefpodoxime particularly suitable for empirical treatment of acute upper respiratory tract infections in adults? Low cost and availability High cure rates and favourable safety profile Once-daily dosing Broad spectrum against viruses13. The bacteriological cure rate difference between Cefpodoxime and Amoxicillin plus Clavulanic acid in AECB is approximately: 5.3% 7.3% 9.3% 11.3%14. Which characteristic of Cefpodoxime contributes most to its effectiveness in treating respiratory tract infections? Low protein binding Superior tissue penetration and antimicrobial activity Minimal drug interactions Extended half-life I have read and agree to the Terms and Conditions .Submit Form